© JPC-PROD/SHUTTERSTOCK MODELS USED FOR ILLUSTRATIVE PURPOSES ONLY
1. World Health Organization. Fact sheet. Influenza (seasonal). Geneva: WHO; 2018. Available online at: www.who.int/mediacentre/factsheets/fs211/en (accessed February 2019).
2. Nair H, Abdullah Brooks W, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011; 378: 1917-1930.
3. US Centers for Disease Control and Prevention. Disease burden of influenza. Atlanta, GA: CDC; 2019. Available online at: www.cdc.gov/flu/about/disease/burden.htm (accessed February 2019).
4. Australian Government Department of Health. 2017 influenza season in Australia. A summary from the National Influenza Surveillance Committee. Canberra: Department of Health; 2017. Available online at: www.health.gov.au/internet/main/publishing.nsf/Content/097F15A91C05FBE7CA2581E20017F09E/$File/2017-season-summary-22112017.pdf (accessed February 2019).
5. Siriwardena AN. Increasing evidence that influenza is a trigger for cardiovascular disease. J Infect Dis 2012; 206: 1636-1638.
6. Gordon A, Reingold A. The burden of influenza: a complex problem. Curr Epidemiol Rep 2018; 5: 1-9.
7. Gozalo PL. The impact of influenza on functional decline. J Am Geriatr Soc 2012; 60: 1260-1267.
8. US Centers for Disease Control and Prevention. Types of influenza viruses. Atlanta, GA: CDC; 2017. Available online at: www.cdc.gov/flu/about/viruses/types.htm (accessed February 2019).
9. Zhou H, Thompson WW, Viboud CG, et al. Hospitalisations associated with influenza and respiratory syncytial virus in the United States 1993-2008. Clin Infect Dis 2012; 54: 1427-1436.
10. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada 1992-2009. PLoS One 2013; 8: e80481.
11. Falsey AR, Baran A, Walsh EE. Should clinical case definitions of influenza in hospitalized older adults include fever? Influenza Other Respir Viruses 2015; 9 Suppl 1: 23-29.
12. Minnesota Department of Health (US). Influenza-like illness in elderly persons. St Paul, MN: Department of Health; 2016. Available online at: www.health.state.mn.us/diseases/flu/ltc/fluelderly.html (accessed February 2019).
13. Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol 2014; 29: 38-42.
14. Govaert TM, Thijs CT, Masurel N, Sprengel MJ, Dinant GJ, Knotterus JA. The efficacy of influenza vaccination in elderly individuals. A randomised double-blind placebo-controlled trial. JAMA 1994; 272: 1661-1665.
15. Godoy P, Romero A, Soldevilla N, et al; The Working Group on Surveillance of Severe Influenza Hospitalized Cases in Catalonia. Influenza vaccine in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010-11 to 2015-16. Euro Surveill 2018; 23(43): pii=1700732. https://doi.org/10.2807/1560-7917.ES.2018.23.43.1700732
16. McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012; 30: 2060-2067.
17. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect 2014; 68: 363-371.
18. Australian Government Department of Health. Chief Medical Officer statement on seasonal flu vaccines [news]. Canberra: Department of Health; 2017. Available online at: beta.health.gov.au/news-and-events/news/statement-from-the-chief-medical-officer-on-seasonal-influenza-vaccines (accessed February 2019).
19. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31: 6122-6128.
20. Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine 2017; 35: 513-520.
21. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard dose influenza vaccine in older adults. N Engl J Med 2014; 371: 635-645.
22. Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine 2017; 35: 2775-2780.
23. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27: 6959-6965.
24. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 7656-7663.
25. Australian Institute of Health and Welfare. 2009 Adult Vaccination Survey: summary results. Cat. no. PHE 135. Canberra: AIHW; 2011. Available online at: www.aihw.gov.au/reports/primary-health-care/2009-adult-vaccination-survey-summary-results (accessed February 2019).
26. Litt J, Rigby K, Duffy J. Australian National Influenza and Pneumococcal Survey in the elderly. Report No. 1. 12/2003 to Commonwealth Department of Health and Ageing. Adelaide: Discipline of General Practice, Flinders University; 2003.
COMPETING INTERESTS: Professor Van Buynder has conducted clinical research on vaccine effectiveness of adjuvanted vaccines via an unrestricted grant from Novartis. He has also received support for research, education and marketing, travel and/or advisory board activities from Seqirus, Sanofi, GlaxoSmithKline, Roche, Pfizer and Novartis.